France· FR:62698206
NEBIVOLOL CRISTERS 5 mg, comprimé quadrisécable
A nebivolol product containing chlorhydrate de nébivolol, registered in France by CRISTERS, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Nebivolol is registered in 16 of 19 countries.
Countries holding a registration under ATC C07AB12 (nebivolol), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 10 of them publish a price we can compare per daily dose
Nebivolol · ATC C07AB12
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nebivolol costs, country by country.
Normalised to the WHO defined daily dose (5 mg), the median price runs from $0.092 in United States to $0.39 in Switzerland — a ×4.2 gap.
- France: $0.14 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Nebivolol · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.39
- ES Spain$0.32
- IT Italy$0.25
- FR France$0.14
- US United States$0.092 (acquisition cost)
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CHLORHYDRATE DE NÉBIVOLOL
- Manufacturer
- CRISTERS
- Country
- France (FR)
- ATC code
- C07AB12
- ATC class
- Nebivolol
- Defined daily dose
- 5 mg, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip133400939829890plaquette(s) thermoformée(s) PVC polyéthylène PVDC aluminium de 30 comprimé(s)EUR 3.72
- cip133400939830261plaquette(s) thermoformée(s) PVC polyéthylène PVDC aluminium de 90 comprimé(s)EUR 10.35
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
273 interactions on record for nebivolol.
Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nebivolol · interactions on record
273 records
- 10 severe
- 202 moderate
- 17 minor
Most severe, free to view
- DolasetronA04AA04severe
- TheophyllinC01EB28severe
- CeritinibL01ED02severe
- CeritinibL01XE28severe
44 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nebivolol in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNEBILETBERLIN-CHEMIE AG, Berlín
- United KingdomHypoloc 5mg tabletsA. Menarini Farmaceutica Internazionale SRL
- United StatesBystolicAllergan, Inc.
- SpainINSUCOR 5 MG COMPRIMIDOS EFGGlenmark Arzneimittel Gmbh
- ItalyLOBIVONGENERAL PHARMA SOLUTIONS S.P.A.
- PolandDanebS-Lab Sp. z o.o.
- SwitzerlandNebilet, TablettenA. Menarini GmbH
- NetherlandsHypoloc tabletten 5 mgMenarini International Operations Luxembourg S.A.
Authorised across Europe · EMA
The same active substance is authorised in 26 EEA countries. Names it is sold under:
- Austria · Nebilan, Nebivolol +pharma
- Belgium · Nebivolol Ab, Nebivolol Eg
- Bulgaria · Nebilan, Nebivolol Sandoz
- Cyprus · Lobivon, Nebivolol Accord
- Czechia · Nebilet, Nebivolol Medreg
- Germany · Nebilet, Nebivolol 089pharm
- Denmark · Hypoloc, Nebivolol Accord
- Estonia · Nebicard, Nebilet
- Spain · Insucor, Lobivon
- Finland · Hypoloc, Nebivolol Accord
- United Kingdom (Northern Ireland) · Nebilet, Nebivolol
- Greece · Bivol, Hypoloc
- Croatia · Massido, Nebilet
- Hungary · Nebibeta, Nebilet
- Ireland · Nebilet, Nebimel
- Italy · Lobivon, Nebilox
- Lithuania · Nebicard, Nebilet
- Luxembourg · Nebivolol Eg, Nobiten
- Latvia · Nebilet, Nebivolol Actavis
- Malta · Nebilet, Nebivolol Atb
- Netherlands · Hypoloc, Lobivon
- Poland · Daneb, Ebivol
- Portugal · Nebilet, Nebivolol Aurovitas
- Romania · Nebilet, Nebivolol Gemax Pharma
- Slovenia · Nebilet, Nebivolol Krka
- Slovakia · Nebilet, Nebitrix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b1a57f17-6633-4b5c-b77c-d7aa4f3d2e45 GET /v1/drugs/b1a57f17-6633-4b5c-b77c-d7aa4f3d2e45?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62698206",
"date_amm": "2009-10-13",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "CHLORHYDRATE DE NÉBIVOLOL",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé quadrisécable",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about nebivolol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.